Keppra (levetiracetam) is not classified as a psychotropic medication. It is officially classified as an anticonvulsant, a drug designed to prevent seizures. However, the line between these categories is blurrier than it might seem, because Keppra works directly on brain chemistry and carries notable psychiatric side effects that overlap with concerns typically associated with psychotropic drugs.
How Keppra Is Classified
Keppra belongs to the anticonvulsant (also called antiepileptic) class of medications. It is FDA-approved to treat epilepsy, either on its own or alongside other seizure medications. It is not approved to treat any psychiatric condition such as depression, anxiety, or bipolar disorder.
The term “psychotropic” broadly refers to any drug that affects mood, thinking, or behavior as its primary purpose. Antidepressants, antipsychotics, and mood stabilizers all fall under that umbrella. Keppra’s primary purpose is seizure control, which is why it sits in the anticonvulsant category rather than the psychotropic one. That said, some anticonvulsants (like valproate and lamotrigine) do double duty as mood stabilizers, which is part of why people wonder whether Keppra fits a similar profile.
Why the Question Comes Up
Keppra acts on the brain in ways that go beyond simply stopping seizures. It binds to a protein called SV2A, which is found throughout the brain’s nerve terminals and plays a key role in how neurons release chemical messengers. By attaching to this protein, Keppra reduces the signaling between overexcited nerve cells. It also inhibits calcium channels inside neurons, which further dials down brain activity. Because it directly alters neurotransmitter release across the brain, not just in seizure-prone areas, it can affect mood and behavior in ways that feel distinctly “psychotropic” to the person taking it.
Researchers have tested whether Keppra could work as a psychiatric treatment. A randomized, double-blind trial published in The Journal of Clinical Psychiatry tested it as an add-on therapy for bipolar depression. Patients received up to 2,500 mg per day for six weeks. The result: Keppra performed no better than a placebo on depression scores or any secondary measures. Unlike some other anticonvulsants, it has not found a second life as a mood stabilizer.
Psychiatric Side Effects Are Real
Even though Keppra is not a psychotropic drug by classification, it carries FDA warnings about significant psychiatric side effects. These are worth understanding, because they’re often the reason people search this question in the first place.
In clinical trials, 7% of patients taking the extended-release form experienced behavioral problems like irritability and aggression, compared to 0% on placebo. About 1% of adults on Keppra developed psychotic symptoms, versus 0.2% on placebo. Two patients in trials were hospitalized for psychosis that developed within the first week of treatment, though both recovered within one to two weeks after stopping the drug.
Keppra also carries a broader warning that applies to all antiepileptic drugs: an increased risk of suicidal thoughts or behavior. Pooled data from 199 clinical trials of 11 different antiepileptic medications found that patients on these drugs had roughly twice the risk of suicidal thinking compared to those on placebo. In practical terms, that translated to about one additional case for every 530 patients treated. This elevated risk appeared as early as one week after starting treatment and persisted throughout.
What This Means If You Take Keppra
The psychiatric side effects of Keppra are well documented enough that neurologists routinely counsel patients about them before starting the medication. If you or someone close to you notices new irritability, aggressive behavior, unusual mood changes, or dark thoughts after starting Keppra, those are recognized side effects of the drug, not something unrelated. These changes tend to appear early, often within the first few weeks.
For most people, Keppra is well tolerated and effective for seizure control. But the subset of patients who do experience behavioral changes can find them disruptive. When that happens, switching to a different anticonvulsant with a lower rate of mood-related side effects is a standard approach. The behavioral symptoms tied to Keppra typically resolve quickly once the medication is stopped or changed.
So while your pharmacy won’t label Keppra as a psychotropic, and your insurance company won’t categorize it that way, it is a brain-active drug with meaningful effects on mood and behavior in a minority of people who take it. The classification matters less than understanding what the drug actually does.